Navigation Links
Continued Uptake of Novartis/Incyte's Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market

BURLINGTON, Mass., Jan. 31, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2021, the continued uptake of Novartis/Incyte's recently launched JAK-2 inhibitor Jakafi (ruxolitinib) will be the greatest driver of growth in the myelofibrosis therapy market in the United States and Europe. Since only a small percentage of patients are eligible for allogeneic stem-cell transplantation—the lone curative treatment for myelofibrosis—the only care available for most patients is treatment of disease symptoms. According to interviewed experts, the entry of ruxolitinib is a significant advance in myelofibrosis treatment because they believe the drug offers clear improvements in constitutional symptoms and reduces the severe splenomegaly experienced by many patients, resulting in an overall better quality of life.


According to Niche Markets and Rare Diseases: Myelofibrosis, JAK-2 inhibition is the focus of considerable development activity in myelofibrosis and up to five new JAK-2 inhibitors could launch for the disease through 2021. Clinical trial data from long-term evaluation of myelofibrosis patients indicated that ruxolitinib improves overall survival in addition to providing sustained relief of constitutional symptoms—these recent analyses will likely accelerate uptake of ruxolitinib and other JAK-2 inhibitors.

"The most promising emerging JAK-2 inhibitor—YM Biosciences' CYT-387—has attracted interest from physicians because early phase trials have shown an effect on anemia in addition to an effect on constitutional symptoms," said Decision Resources Senior Vice President Cynthia Mundy , Ph.D. "Also, Gilead's recent decision to acquire YM Biosciences to gain access to the drug suggests Gilead expects CYT-387 to emerge as a formidable competitor to ruxolitinib and that this agent could capture substantial market share."

The report also finds that, although interviewed experts are enthusiastic about treatments that offer better management of myelofibrotic symptoms and improvements in quality of life, they indicate they are likely to continue using conventional treatment regimens in many of their patients, particularly those assessed as having lower risk. As a result, although ruxolitinib will experience significant adoption in the myelofibrosis market, hydroxyurea (Bristol-Myers Squibb's Hydrea, generics) will continue to be widely used to treat constitutional symptoms. Similarly, Celgene's emerging immunomodulator pomalidomide will not displace use of the older, related drugs—Celgene's Thalomid and Revlimid (lenolidomide).

About Myelofibrosis
Myelofibrosis is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kibow Biotech Marks Its Continued Growth with Relocation to Larger Facilities
2. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
3. Anoto Announces Continued Worldwide Expansion in Healthcare
4. Education and Collaboration Key to Continued Progress in Fighting Rogue Online Prescription Drug Sellers, Reports NABP
5. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
6. Lower Operating Expense Augments Digital X-rays Uptake Across Industries, Finds Frost & Sullivan
7. Endoscopy Devices Market to 2018 - Demand for Cost-Effective, Minimally Invasive Procedures and Reimbursement for New Indications to Increase Uptake
8. First Paralyzed Formula Race Car Drivers "Road to Indy" Sponsored By Coloplast
9. Safe Driving Prescription for Senior Drivers
10. Nedbank Golf Challenge a Driver for Breast Cancer in South Africa
11. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Therapeutic Drug Monitoring (TDM) ... Competitive Intelligence, Emerging Opportunities"  report to ... ) has announced the addition of ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... 2015 ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
Breaking Medicine Technology:
(Date:11/26/2015)... , ... November 26, 2015 , ... ... real-time eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean ... Nuclear Medicine tests directly from their electronic medical record (EMR) without the need ...
(Date:11/26/2015)... ... 2015 , ... Jobs in hospital medical laboratories and in the imaging field ... agency Aureus Medical Group . These fields, as well as travel ... for healthcare jobs through the company’s website, , The leading healthcare ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios ... titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new ... any font, giving users limitless opportunities to stylize and create designs quickly and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers ... on mammography, according to a study published online in the journal Radiology. Researchers ... mammography may necessitate a change in treatment. , Breast MRI is the most ...
(Date:11/25/2015)... ... 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared sauna ... and far-infrared saunas. , For traditional saunas, Finnleo is offering 20% ... wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably grown ...
Breaking Medicine News(10 mins):